Oncology Market Access Europe – Payer and Industry Perspectives answers your questions:
What are payers looking for when making decisions regarding oncology reimbursement?
How are HTAs and other challenges affecting market access and what insight do payers offer?
How do payer decisions vary from market to market and what factors influence those decisions?
What will be the future role of real world data in payer decision-making?
What role do risk-sharing schemes, expanded access programmes and other pricing schemes play?
What factors should companies take into account when planning market access strategies?
Which innovations, such as PD-1 inhibitors, vaccines, personalised medicine and companion diagnostics show the most promise?
Oncology market access faces significant and mounting challenges as payers increase data requirements and financial austerity holds sway over decision-making. As pricing and reimbursement requirements become more stringent, issues of development cost, risk and slow market growth are at the forefront. In order to achieve market access success, companies need to adapt their approach and include health outcomes data to meet payer requirements.
Based on interviews and surveys with experts from the UK, Germany, Italy, France and Spain, FirstWord’s Oncology Market Access Europe – Payer and Industry Perspectives lays out the current – and growing – challenges facing companies in getting drugs to the European market. Filled with compelling insight into the most pressing issues ranging from changing payer data requirements and financial austerity to the adoption of formalised HTA, the report offers critical strategies, knowledge and a roadmap to the future.
A report for the whole industry
The challenges for oncology market access are expected to increase and grow in the near future, making Oncology Market Access Europe – Payer and Industry Perspectives a must-read report not only for those working in market access, brand strategy, business development and licensing, but in biosimilars, payer relationships and drug innovation.
Key benefits, features and insights
Oncology market access is evolving and requires constant updates to keep abreast of changes. In this report, stakeholders will:
Gain insight into both the industry and payer perspectives, with particular reference to the increasing importance of robust clinical health outcomes data
Understand the key issues affecting access and how they vary between markets
Learn about key strategies for success, such as patient access schemes, price-volume agreements and price capping
Identify what effective strategies are used by which companies and why they work
Understand why the industry needs to adapt to an evolving and challenging landscape
Gain insight into how market access issues are driving decisions around R&D
Insight into the innovative strategies being employed to gain market access
Overview of new drug approvals and oncology pipeline prospects such as cancer vaccines, niche indications and personalised medicine
Examination of the role of HTAs from both payer and industry perspectives
Key findings regarding the importance of early inclusion of market access considerations
How oncology market access varies from country to country and why
Complete overview of current oncology market access trends and challenges
The payer perspective on everything from transparency in information to the use of health outcomes data in decision making
How payers view the HTA process and its role in the short to medium term
Key experts interviewed
UK payer: Deputy Head of Medicines Management for a PCT with regional and local funding and budgetary decision making responsibility
German payer: Head of a national budgetary committee with national, regional and local funding and budgetary decision making responsibility
Italian payer: Pharmacist involved in purchasing of drugs and devices for hospital and with national, regional and local funding and budgetary decision making responsibility
Spanish payer: Professor of health economics and advisor to the Ministry of Health on pricing and reimbursement issues, with national, regional and local funding and budgetary decision making responsibility
French payer – Hospital pharmacist involved in buying medical products including drugs and medical devices for a group of nine hospitals with regional and local funding and budgetary decision making responsibility
Former oncology marketing manager, BMS
Oncology marketing manager, GSK
Oncology medical manager, GSK
Oncology market access, Pfizer
Get Industry Insights. Simply.
- Latest reports & slideshows with insights from top research analysts
- 60 Million searchable statistics with tables, figures & datasets
- More than 25,000 trusted sources